"We are grateful to the thousands of people who have participated in the Framingham Heart Study over the last six decades -- their cooperation will again help scientists make great strides in understanding, preventing, and treating cardiovascular diseases."
Only information from participants who have consented to sharing their specimens and data with commercial researchers will be used, and all shared information will be de-identified to protect participants' privacy.
"The collaborative research planned under this agreement focuses on blood biomarkers of atherosclerotic vascular disease as determined by multiple imaging modalities," said Valentin Fuster, M.D., Ph.D. director of Mount Sinai Heart at the Mt. Sinai Medical Center in New York, NY, and chairman of another cardiovascular biomarker initiative known as the HRP Initiative.
"This will further contribute to our insight in the discrepancies between risk factors and disease -- some people with multiple risk factors are disease-free, while others with a favorable risk factor profile have extensive atherosclerotic vascular disease."
"It is an honor and a privilege to be able to participate in this important research using the Framingham biosamples," said Pieter Muntendam, M.D., Chief Executive Officer of BG Medicine (www.bg-medicine.com). "Use of these advanced research platforms now enable the kind of biomarker research that was impossible just a couple of years ago."
BG Medicine also is playing a lead role in the HRP Initiative (www.HRPInitiative.com). The HRP initiative is conducting a number of studies to discover and validate novel blood or imaging biomarkers of atherosclerosis and risk for atherothrombosis.'/>"/>
|SOURCE BG Medicine|
Copyright©2009 PR Newswire.
All rights reserved